Akur8 Teams up With Pet Health Unicorn Bought By Many / ManyPets
Akur8 is pleased to announce the collaboration with pet health and insurance company Bought By Many to help boost the insurtech’s pricing capabilities. Through the partnership, Akur8 reinforces its presence in the UK, and further expands its area of expertise with a new line of business: pet health and insurance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220215005001/en/
Specifically developed for insurers, Akur8’s solution enhances pricing processes by automating risk modeling, using Transparent Artificial Intelligence proprietary technology. Core benefits for insurers include increased predictive performance and speed-to-accuracy for higher market reactivity and immediate business impact, while maintaining full transparency and control on the models created.
Since launching exclusively into pet insurance in the UK in 2017, Bought By Many has quickly become a fintech success story. The company expanded into the Swedish market in 2019 and earlier this year crossed the Atlantic to launch a state-by-state roll out in the US, both under the ManyPets brand. The group now insures half a million pets globally. In June 2021, the company gained unicorn status after securing a valuation of over $2bn following a $350m Series D funding round through its holding company Many Group. The investment has helped support Bought By Many’s global expansion and drive product development beyond its market-leading insurance offer.
Choosing Akur8’s best-in-class solution aligns with Bought By Many’s vision of making the world a better place for pets and will provide Bought By Many with enhanced pricing capabilities, including exceptionally fast and transparent automated modelling.
“Bought By Many is our first customer specialised in pet insurance, and we are delighted to announce this collaboration! Akur8 is honoured to support Bought By Many in its fast and impressive global development. This new alliance reflects Bought By Many's dedication to innovation in technology and service as well as transparency”, said Samuel Falmagne, CEO at Akur8.
“We are thrilled to add pet insurance as a new line of business in our portfolio, and to strengthen our position in the UK insurance market. As an exponentially growing insurer, Bought By Many is a great reference and we are proud to be working with them”, stated Brune de Linares, Chief of Sales at Akur8.
“We are continuing to revolutionise how owners access pet health services, products and advice. This means improving all stages of the pet ownership journey including pricing. Working with Akur8 and a new pricing solution will help us further improve our time-to-market and to deliver an even more outstanding customer experience as we continue to grow”, commented Charlotte Halkett, Chief Commercial Officer at Bought By Many.
“We are very pleased with Akur8’s performance. This solution will allow us to improve our modelling performance and to boost our speed-to-market, which is key to fuel our ambitious growth plans”, added Charlotte Ball, Pricing Lead at Bought By Many.
About Akur8
Akur8 is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.
Meet Bought By Many & ManyPets.
UK | SWEDEN | USA
We’re making the world a better place for pets and their parents with award-winning pet insurance and access to pet health and wellness services. We're reaching pet parents around the world, and now look after half a million pets globally. There’s a reason pet owners voted us Pet Insurance Provider Of The Year 2021. Actually, there are a few reasons. We offer the most comprehensive pet insurance policy in the UK with up to £15,000 of annual vet fee cover that resets every year plus we include cover for dental illness as standard. We help pet parents take care of all aspects of their pet’s health - for happier, healthier pets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005001/en/
Contact information
Media
For Akur8
Anne-Laure Klein
+33 (0)6 63 79 44 74
anne-laure.klein@akur8.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom